• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A two-stage procedure for survival studies with surrogate endpoints.

作者信息

Flandre P, O'Quigley J

机构信息

INSERM U 436, CHU Pitié-Salpêtrière, Paris, France.

出版信息

Biometrics. 1995 Sep;51(3):969-76.

PMID:7548712
Abstract

A two-stage procedure for survival studies with surrogate endpoints is proposed. The objective of the procedure is to reduce the duration of a survival study relative to classical procedure. A surrogate endpoint is an event which is related to survival time and may occur earlier during follow up. In the first stage, all patients are followed to the primary endpoint in order to evaluate the strength of the relationship between the surrogate endpoint and survival. In the second stage, follow up is terminated on patients who reach the surrogate endpoint. Indirect inferences on the survival endpoint is now possible by virtue of the first stage analysis. We present methods for data collected in the two-stage procedure, for estimating the survivorship function, S(t), and for comparing two treatment groups using a non-parametric permutation test. The methods are applied to the results of a study of resected lung cancer.

摘要

相似文献

1
A two-stage procedure for survival studies with surrogate endpoints.
Biometrics. 1995 Sep;51(3):969-76.
2
Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.替代终点验证过程中的决策是否会随治疗效果的显著性水平而改变?关于替代终点验证的一项提议。
Contemp Clin Trials. 2009 Jan;30(1):8-12. doi: 10.1016/j.cct.2008.08.006. Epub 2008 Sep 9.
3
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
4
Design and analysis of group sequential logrank tests in maximum duration versus information trials.最大持续时间与信息量试验中序贯对数秩检验的设计与分析
Biometrics. 1995 Sep;51(3):988-1000.
5
[Reduction in follow-up period of a study using criteria supplemental to death].[使用除死亡外的标准缩短研究随访期]
Rev Epidemiol Sante Publique. 1993;41(6):494-500.
6
An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.术前贫血与接受单纯手术治疗的早期非小细胞肺癌患者生存率降低之间的关联。
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1438-43. doi: 10.1016/j.ijrobp.2004.12.038.
7
Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections.IA期非小细胞肺癌的肺叶下切除:肺段切除术相比楔形切除术,癌症相关生存率显著更高。
Eur J Cardiothorac Surg. 2008 Apr;33(4):728-34. doi: 10.1016/j.ejcts.2007.12.048. Epub 2008 Feb 7.
8
Designing phase II studies in cancer with time-to-event endpoints.设计以事件发生时间为终点的癌症II期研究。
Clin Trials. 2008;5(3):209-21. doi: 10.1177/1740774508091748.
9
A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.一种使用二元替代终点来预测干预对真实终点影响的简单荟萃分析方法。
Biostatistics. 2006 Jan;7(1):58-70. doi: 10.1093/biostatistics/kxi040. Epub 2005 Jun 22.
10
Sequential analysis of censored survival data from three treatment groups.来自三个治疗组的删失生存数据的序贯分析。
Biometrics. 1997 Sep;53(3):807-22.

引用本文的文献

1
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?统计考虑和临床肺癌研究的终点:无进展生存期 (PFS) 是否可以替代总生存期 (OS) 作为晚期非小细胞肺癌临床试验的有效终点?
Transl Lung Cancer Res. 2012 Mar;1(1):26-35. doi: 10.3978/j.issn.2218-6751.2011.12.08.